Pluristem Therapeutics, Inc. (NASDAQ: PSTI), interview with co-CEO Yaky Yanay. Yaky explains Pluristem’s regenerative medicine technologies, which use placenta-derived cell products, and address multi-billion health markets.
Pluristem has 3 products in late stage FDA clinical trials, and at an inflection point, as it will begin generating “several million in revenue” in 2019 from it’s first product, PLX-PAD, which treats critical limb ischemia, and available via the FDA’s Expanded Access Program, starting January 2019.
Yaky Yanay also discusses Pluristem’s IP portfolio, scalable . . .
This content is available to members only.
If you are an existing member, please LOGIN
Not a member? Sign up for a FREE trial account now ($49 per month value), and get immediate access.
Register New Account
Institutional / team access subscriptions, contact Melissa Walters 212-871-2057 ext 2